These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26971226)

  • 61. FANCI is a negative regulator of Akt activation.
    Zhang X; Lu X; Akhter S; Georgescu MM; Legerski RJ
    Cell Cycle; 2016; 15(8):1134-43. PubMed ID: 27097374
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PHLPPing through history: a decade in the life of PHLPP phosphatases.
    Grzechnik AT; Newton AC
    Biochem Soc Trans; 2016 Dec; 44(6):1675-1682. PubMed ID: 27913677
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Prognostic significance of inflammatory indicators for advanced-stage diffuse large B-cell lymphoma].
    Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Sun Y; Shi YK
    Zhonghua Yi Xue Za Zhi; 2018 Apr; 98(16):1250-1255. PubMed ID: 29747314
    [No Abstract]   [Full Text] [Related]  

  • 64. Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer.
    Xing P; Wang H; Yang S; Han X; Sun Y; Shi Y
    BMC Immunol; 2018 Apr; 19(1):14. PubMed ID: 29661145
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [The development of biosimilars in oncology].
    Jiang SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Emerging roles of PHLPP phosphatases in lung cancer.
    Xia X; Pi W; Chen M; Wang W; Cai D; Wang X; Lan Y; Yang H
    Front Oncol; 2023; 13():1216131. PubMed ID: 37576883
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PHLPP1 deficiency protects against age-related intervertebral disc degeneration.
    Zhang C; Joseph KM; Khan NM; Diaz-Hernandez ME; Drissi H; Illien-Junger S
    JOR Spine; 2022 Dec; 5(4):e1224. PubMed ID: 36601379
    [TBL] [Abstract][Full Text] [Related]  

  • 69. PHLPP Signaling in Immune Cells.
    Lordén G; Lam AJ; Levings MK; Newton AC
    Curr Top Microbiol Immunol; 2022; 436():117-143. PubMed ID: 36243842
    [TBL] [Abstract][Full Text] [Related]  

  • 70. ZERO-INFLATED QUANTILE RANK-SCORE BASED TEST (ZIQRANK) WITH APPLICATION TO SCRNA-SEQ DIFFERENTIAL GENE EXPRESSION ANALYSIS.
    Ling W; Zhang W; Cheng B; Wei Y
    Ann Appl Stat; 2021 Dec; 15(4):1673-1696. PubMed ID: 35116085
    [TBL] [Abstract][Full Text] [Related]  

  • 71. On the PHLPPside: Emerging roles of PHLPP phosphatases in the heart.
    Lemoine KA; Fassas JM; Ohannesian SH; Purcell NH
    Cell Signal; 2021 Oct; 86():110097. PubMed ID: 34320369
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Multifaceted Role of CMA in Glioma: Enemy or Ally?
    Lo Dico A; Martelli C; Diceglie C; Ottobrini L
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672324
    [TBL] [Abstract][Full Text] [Related]  

  • 73. MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-κB activation.
    Liu X; Yue C; Shi L; Liu G; Cao Q; Shan Q; Wang Y; Chen X; Li H; Wang J; Gao S; Niu M; Yu R
    J Cell Mol Med; 2020 Jul; 24(13):7550-7562. PubMed ID: 32452133
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of chromosomal region maintenance 1 suppresses the migration and invasion of glioma cells via inactivation of the STAT3/MMP2 signaling pathway.
    Shan Q; Li S; Cao Q; Yue C; Niu M; Chen X; Shi L; Li H; Gao S; Liang J; Yu R; Liu X
    Korean J Physiol Pharmacol; 2020 May; 24(3):193-201. PubMed ID: 32392910
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inhibition of PHLPP1 ameliorates cardiac dysfunction via activation of the PI3K/Akt/mTOR signalling pathway in diabetic cardiomyopathy.
    Zhang M; Wang X; Liu M; Liu D; Pan J; Tian J; Jin T; Xu Y; An F
    J Cell Mol Med; 2020 Apr; 24(8):4612-4623. PubMed ID: 32150791
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma.
    Lo Dico A; Salvatore D; Martelli C; Ronchi D; Diceglie C; Lucignani G; Ottobrini L
    Cells; 2019 Oct; 8(11):. PubMed ID: 31653091
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Candidate Biomarkers and Molecular Mechanism Investigation for Glioblastoma Multiforme Utilizing WGCNA.
    Yang Q; Wang R; Wei B; Peng C; Wang L; Hu G; Kong D; Du C
    Biomed Res Int; 2018; 2018():4246703. PubMed ID: 30356407
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The impact of phosphatases on proliferative and survival signaling in cancer.
    Narla G; Sangodkar J; Ryder CB
    Cell Mol Life Sci; 2018 Aug; 75(15):2695-2718. PubMed ID: 29725697
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
    Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
    J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Role of PHLPP1 in inflammation response: Its loss contributes to gliomas development and progression.
    Teng DC; Sun J; An YQ; Hu ZH; Liu P; Ma YC; Han B; Shi Y
    Int Immunopharmacol; 2016 May; 34():229-234. PubMed ID: 26971226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.